Target Validation in Drug Discovery for Neglected Tropical Diseases
Author Information
Author(s): Wyatt Paul G, Gilbert Ian H, Read Kevin D, Fairlamb Alan H
Primary Institution: Drug Discovery Unit, College of Life Sciences, University of Dundee
Hypothesis
The study aims to illustrate how molecular targets are assessed for entry into a drug discovery pipeline based on the needs defined by the Target Product Profile (TPP).
Conclusion
The review emphasizes the importance of using Target Product Profiles to guide drug discovery efforts for neglected tropical diseases.
Supporting Evidence
- Neglected tropical diseases affect approximately 1 billion people worldwide.
- Only 1% of new drugs approved in the last 25 years were for neglected diseases.
- High attrition rates in drug discovery highlight the need for better target validation.
Takeaway
This study talks about how scientists can find better medicines for diseases that are often ignored by focusing on what patients really need from new drugs.
Methodology
The review discusses the assessment of molecular targets and the use of Target Product Profiles in drug discovery.
Limitations
The study highlights the high attrition rates in drug discovery and the challenges in validating drug targets.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website